Washington University School of Medicine in St. Louis | Strategic Alliance Partners

March 27, 2015

Brian Van Tine, MD, PhD, assistant professor of medicine, Division of Oncology, Section of Medical Oncology, Washington University School of Medicine, discusses sequencing in gastrointestinal stromal tumors (GIST).

March 11, 2015

OncLive interviewed Ravi Vij, MD, associate professor, Division of Oncology, Section of Bone Marrow Transplantation, Washington University School of Medicine and the Siteman Cancer Center, on what the future holds for stem cell transplantation in multiple myeloma.

November 10, 2014

Amid a coming storm of demographic trends signaling a sharp increase in the number of older people diagnosed with cancer in the United States, researchers are developing new geriatric assessment tools to help oncology specialists better manage this patient population.

July 23, 2014

Brian A. Van Tine, MD, PhD, assistant professor, Washington University School of Medicine in St. Louis, discusses some potential novel treatment modalities for the treatment of sarcoma.

June 18, 2014

Kenneth R. Carson, MD, assistant professor, Division of Oncology, Washington University, discusses mogamulizumab as a potential treatment for patients with relapsed or refractory cutaneous T cell lymphoma (CTCL).

March 04, 2014

As melanoma becomes more prevalent and more lethal in the United States, a multidisciplinary approach for treating inoperable in-transit metastases has proved to be a viable and valuable option.

February 17, 2014

High-tech eyewear could soon help surgeons remove tumors from patients with breast cancer or melanoma by allowing them to see the margins of tumors more accurately when a dye is used to fluoresce a tumor's borders.

December 19, 2013

The question of whether fulvestrant (Faslodex) should be moved forward in the treatment timeline for postmenopausal women with advanced, hormone receptor (HR)-positive breast cancer is being evaluated in an international, randomized phase III trial.

December 17, 2013

Two years after the FDA denied a request to expand the indication of finasteride and other 5α-reductase inhibitors to prevent prostate cancer, a major study has cast doubt on the concerns that prompted the denial: that the drug raised the risk of more lethal cancers.

October 24, 2013

One of the privileges of working in an academic medical center is the luxury of being able to subspecialize in the treatment of sarcoma. Nationwide, there may be 40 to 50 medical oncologists who focus on the treatment of adult soft tissue and bone sarcoma.

October 07, 2013

The National Cancer Institute, part of the National Institutes of Health, has awarded two major grants totaling $26 million to leukemia researchers and physicians at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis.

September 18, 2013

Rebecca L. Aft, MD, PhD, professor of surgery at the Washington University School of Medicine in St. Louis and a physician at Siteman Cancer Center, discusses the use of bisphosphonates for patients with breast cancer.

August 27, 2013

Matthew J. Ellis, MD, PhD, professor, Department of Medicine, Oncology Division, Breast Oncology Section, Washington University School of Medicine in St. Louis, Missouri, discusses the future of The Cancer Genome Atlas project.

August 15, 2013

Bruce Roth, MD, from the Siteman Cancer Center, Washington University School of Medicine, discusses the treatment of several cancers with bevacizumab.

August 12, 2013

Brian A. Van Tine, MD, PhD, Assistant Professor, Washington University School of Medicine in St. Louis, discusses identifying biomarkers in sarcomas.

July 29, 2013

Jeffrey D. Bradley, MD, Professor, Radiation Oncology, Washington University School of Medicine in St. Louis, discusses ongoing research involving radiation therapy for lung cancer.

July 24, 2013

Rebecca L. Aft, MD, PhD, from the Siteman Cancer Center, discusses the need to identify markers for patients with micrometastatic disease.

June 26, 2013

In the past year, clinical laboratories have begun determining the tumor mutational status of multiple genes simultaneously using next-generation sequencing platforms.

June 18, 2013

Jeffrey D. Bradley, MD, Professor, Radiation Oncology, Washington University School of Medicine in St. Louis, discusses the background of the phase III RTOG 0617 study.

March 08, 2013

Ron Bose, MD, PhD, from the Siteman Cancer Center, discusses the prevalence of HER2 gene mutations in patients diagnosed with breast cancer.